Status: Not yet recruiting
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
This study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.
Participants needed: 30
Trial details
Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Jin LIUpdated: Mar 12, 2026Locations: 1
Eligibility criteria
Age: 18-75 years old, female; [+14]
Patients participating in other clinical trials at the same time, unless they ar... [+16]